Discovery of a highly potent and orally available importin-β1 inhibitor that overcomes enzalutamide-resistance in advanced prostate cancer

Discovery of a highly potent and orally available importin-β1 inhibitor that overcomes enzalutamide-resistance in advanced prostate cancer

Nuclear transporter importin-β1 is emerging as an attractive target by virtue of its prevalence in many cancers. However, the lack of druggable inhibitors restricts its therapeutic proof of concept. In the present work, we optimized a natural importin-β1 inhibitor DD1 to afford an improved analog DD...

Full description

Bibliographic Details
Main Authors: Jia-Luo Huang, Xue-Long Yan, Dong Huang, Lu Gan, Huahua Gao, Run-Zhu Fan, Shen Li, Fang-Yu Yuan, Xinying Zhu, Gui-Hua Tang, Hong-Wu Chen, Junjian Wang, Sheng Yin
Format: Article
Language:English
Published: Elsevier 2023-12-01
Series:Acta Pharmaceutica Sinica B
Subjects:
Importin-β1
CRPC
Drug discovery
Enzalutamide-resistance
Natural product
Cancer
Online Access:http://www.sciencedirect.com/science/article/pii/S2211383523002794

Internet

http://www.sciencedirect.com/science/article/pii/S2211383523002794

Similar Items